Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BTIG Maintains Bullish View on Paratek Pharmaceuticals (PRTK) Following Ad Com Briefing Docs
August 6, 2018 2:05 PM EDTBTIG analyst Robert Hazlett reiterated a Buy rating and $56 price target on Paratek Pharmaceuticals (NASDAQ: PRTK) following FDA briefing documents for Omadacycline.
Hazlett commented, "In our view, there appears little concern regarding ABSSSI (skin) indication for Wednesdays upcoming FDA Ad Com for Omadacycline; we view a recommendation for Omadacyclines approval in ABSSSI as highly likely. The... More
